Kringle Pharma Posts Narrower Quarterly Loss but Confirms Deep Full-Year Deficit Forecast

An update from Kringle Pharma, Inc. ( (JP:4884) ) is now available.

Kringle Pharma reported net sales of ¥18 million for the three months ended December 31, 2025, flat year on year, while operating and ordinary losses narrowed slightly to around ¥199–¥200 million, resulting in a quarterly net loss of ¥201 million and a basic loss per share of ¥28.20. Total assets declined to ¥1,990 million and the equity ratio edged down to 59.7%, the company maintained a zero-dividend policy, and it reaffirmed its full-year forecast for flat sales of ¥72 million alongside a significantly larger projected loss of about ¥1.17 billion, underscoring ongoing heavy investment and sustained financial pressure into fiscal 2026.

Kringle Pharma’s financial position softened slightly this quarter as net assets decreased to ¥1,220 million, reflecting continued losses despite stable top-line performance. With no revisions to its earnings or dividend outlook and no change in accounting policies, the company signals operational and strategic continuity, but the projected deep full-year loss highlights persistent profitability challenges for investors and other stakeholders.

The most recent analyst rating on (JP:4884) stock is a Hold with a Yen359.00 price target. To see the full list of analyst forecasts on Kringle Pharma, Inc. stock, see the JP:4884 Stock Forecast page.

More about Kringle Pharma, Inc.

Kringle Pharma, Inc. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange. The company focuses on pharmaceutical R&D and derives modest net sales while remaining in an investment phase, reflected in continued operating losses and the absence of dividend payments, indicating a priority on funding development over shareholder returns.

Average Trading Volume: 72,530

Technical Sentiment Signal: Sell

Current Market Cap: Yen2.73B

Find detailed analytics on 4884 stock on TipRanks’ Stock Analysis page.